Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Iovance Biotherapeutics (IOVA) over the last 12 years, with Q3 2025 value amounting to $162.4 million.

  • Iovance Biotherapeutics' Operating Expenses rose 998.16% to $162.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $666.9 million, marking a year-over-year increase of 2804.85%. This contributed to the annual value of $559.3 million for FY2024, which is 2113.71% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Operating Expenses stood at $162.4 million for Q3 2025, which was up 998.16% from $173.7 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Operating Expenses peaked at $173.7 million during Q2 2025, and registered a low of $110.3 million during Q2 2023.
  • Over the past 3 years, Iovance Biotherapeutics' median Operating Expenses value was $133.0 million (recorded in 2024), while the average stood at $138.9 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 683.86% in 2024, then soared by 4399.64% in 2025.
  • Over the past 3 years, Iovance Biotherapeutics' Operating Expenses (Quarter) stood at $121.7 million in 2023, then skyrocketed by 31.65% to $160.3 million in 2024, then grew by 1.3% to $162.4 million in 2025.
  • Its last three reported values are $162.4 million in Q3 2025, $173.7 million for Q2 2025, and $170.5 million during Q1 2025.